Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Avenue Therapeutics Inc (ATXI)

Avenue Therapeutics Inc (ATXI)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,754
  • Shares Outstanding, K 44,261
  • Annual Sales, $ 0 K
  • Annual Income, $ -10,380 K
  • 60-Month Beta -0.25
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.92
Trade ATXI with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.27
  • Most Recent Earnings $0.56 on 03/18/24
  • Latest Earnings Date 05/10/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.1400 +9.00%
on 03/25/24
0.2000 -23.70%
on 03/08/24
-0.0019 (-1.23%)
since 02/27/24
3-Month
0.1125 +35.64%
on 02/07/24
0.3529 -56.76%
on 01/04/24
-0.0103 (-6.32%)
since 12/27/23
52-Week
0.1125 +35.64%
on 02/07/24
1.3600 -88.78%
on 04/05/23
-0.9274 (-85.87%)
since 03/27/23

Most Recent Stories

More News
S&P Futures Climb as Investors Weigh Economic Outlook, U.S. Bank Earnings on Tap

June S&P 500 futures (ESM23) are trending up +0.34% this morning after three major U.S. benchmark indices ended the regular session higher as market participants digested the latest batch of corporate...

ESM23 : 4,453.35s (+0.61%)
SCHW : 72.38 (+1.94%)
RXDX : 199.92 (+0.09%)
STT : 76.88 (+0.92%)
GOOGL : 150.87 (+0.13%)
JNJ : 157.96 (+1.41%)
BAC : 37.81 (+1.94%)
NFLX : 613.53 (-2.50%)
LMT : 456.78 (+2.42%)
GS : 415.25 (+2.23%)
ERICB.S.DX : 57.790 (-0.33%)
ATXI : 0.1526 (+1.06%)
AnnJi Pharmaceutical Announced A Licensing Agreement With Avenue Therapeutics To Develop And Commercialize AJ201, A First-In-Class Clinical Asset For The Treatment Of Kennedy's Disease

/PRNewswire/ -- AnnJi Pharmaceutical Co. (AnnJi) has entered into an exclusive license agreement with Avenue Therapeutics Inc. (Avenue, NASDAQ: ATXI) for the...

ATXI : 0.1526 (+1.06%)
Pre-Market Brief: Stocks Mixed as Key U.S. Payrolls Data Looms

December S&P 500 futures (ESZ22) are trending down -0.12% this morning after three major US benchmark indices extended declines for the second successive trading session as investors digested remarks from...

ESZ22 : 3,871.47s (-0.66%)
AMD : 179.59 (+0.97%)
NVDA : 902.50 (-2.50%)
DKNG : 45.35 (-6.84%)
ATXI : 0.1526 (+1.06%)
LEVI : 19.37 (+3.03%)
APRN : 12.99 (-0.08%)
Avenue Therapeutics Announces Outcome of FDA Advisory Committee Meeting on IV Tramadol

NEW YORK, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous...

ATXI : 0.1526 (+1.06%)
Avenue Therapeutics Stock Trading Halted Today

FDA Advisory Committee to review IV tramadol New Drug Application...

ATXI : 0.1526 (+1.06%)
Aegis Capital Corp. Acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)

NEW YORK, NY / ACCESSWIRE / December 15, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therapeutics...

ATXI : 0.1526 (+1.06%)
Avenue Therapeutics Announces Closing of Public Offering of Common Stock

NEW YORK, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of...

ATXI : 0.1526 (+1.06%)
Avenue Therapeutics Prices $2.0 Million Underwritten Public Offering of Common Stock

NEW YORK, Dec. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous...

ATXI : 0.1526 (+1.06%)
Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous...

ATXI : 0.1526 (+1.06%)
Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)

NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therapeutics...

ATXI : 0.1526 (+1.06%)
FBIO : 2.17 (+12.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Avenue Therapeutics, Inc. is a specialty pharmaceutical company. It acquires, licenses, develops and commercializes products principally for use in the acute/intensive care hospital setting. Avenue Therapeutics, Inc. is based in New York, United States.

See More

Key Turning Points

3rd Resistance Point 0.1631
2nd Resistance Point 0.1593
1st Resistance Point 0.1559
Last Price 0.1526
1st Support Level 0.1487
2nd Support Level 0.1449
3rd Support Level 0.1415

See More

52-Week High 1.3600
Fibonacci 61.8% 0.8835
Fibonacci 50% 0.7362
Fibonacci 38.2% 0.5890
Last Price 0.1526
52-Week Low 0.1125

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar